OBR Daily Commentary

forumImage

Judging Cancer Drugs by Clinical, Not Statistical, Measures

(Medscape Medical News) Nov 4, 2016 - A new study of 277 cancer drug clinical trials found that even when drugs provide a statistically significant benefit, they usually don't provide a clinically significant benefit; time for a new approach to approvals?

Read Article arrow

Dean Gesme, MD (Posted: November 07, 2016)

quotesThis will become a critically important issue in the very near future as ever increasing drug prices need to be translated into an environment ruled by value based care contracts which enshrines total cost of care metrics into the payment scheme.quotes

Add Comment 1 Comment
forumImage

Removal of Lobe Instead of Total Thyroid May Benefit Patients after a Suspicious Biopsy for Papillary Thyroid Cancer

(American College of Surgeons) Oct 19, 2016 - Lobectomy is less expensive but more clinically effective than total thyroidectomy. Most Americans with thyroid cancer have an operation to remove the thyroid gland, but those with a smaller, less-threatening form of thyroid cancer may be missing out on a less extensive, less costly, and safer operation that’s actually more effective in treating their cancer, according to study results presented at the 2016 Clinical Congress of the American College of Surgeons.

Read Article arrow

Dean Gesme, MD (Posted: October 20, 2016)

quotesAn important step in reducing over treatment, excessive anxiety, unnecessary follow up testing and controlling costs for the majority of patients with newly sidcovered well differentiated thyroid neoplasms.quotes

Add Comment 1 Comment
forumImage

Is Indication-specific Pricing for Cancer Drugs on the Horizon?

(Cancer Therapy Advisor) Oct 7, 2016 - The clinical benefits of a drug can vary widely among different indications or different patient subpopulations within the same indication.

Read Article arrow

Dean Gesme, MD (Posted: October 11, 2016)

quotesWhile indication based value pricing is a highly logical approach, it defies the ability of our current health payment IT infrastructure in reality. Another great concept held hostage to outdated information systems' investments in the healthcare world!quotes

Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Professor and Chair, Department of Radiation Oncology...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Health Policy
member photo
Joseph Bailes, MD

National Health Policy Expert...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Professor and Physician-in-Chief of the Ohios State Uni...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...